Needham raised the firm’s price target on Establishment Labs (ESTA) to $84 from $70 and keeps a Buy rating on the shares. The company has multiple growth drivers, including US breast augmentation, US breast reconstruction, and its minimally invasive procedures, the analyst tells investors in a research note. Establishment Labs’ growth drivers indicates that it should be able to sustain strong double-digit growth for 5 years and beyond, the firm added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs price target raised to $81 from $70 at BTIG
- Establishment Labs price target raised to $70 from $48 at Needham
- Establishment Labs price target raised to $72 from $60 at Canaccord
- Establishment Labs price target raised to $71 from $45 at JPMorgan
- Establishment Labs price target raised to $85 from $70 at Mizuho